Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Bio-Works Technologies AB's FCF Yield % or its related term are showing as below:
XSAT:BIOWKS'
s FCF Yield % Range Over the Past 10 Years
Min: -83.44 Med: -13.26 Max: -1.77
Current: -2.69
During the past 11 years, the highest FCF Yield % of Bio-Works Technologies AB was -1.77%. The lowest was -83.44%. And the median was -13.26%.
XSAT:BIOWKS's FCF Yield % is ranked worse than 58.96% of 848
companies
in the Medical Devices & Instruments industry
Industry Median: -0.57
vs XSAT:BIOWKS: -2.69
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Bio-Works Technologies AB FCF Yield % Related Terms
Bio-Works Technologies AB FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSAT:BIOWKS vs ISRG, BDX, MDLN: FCF Yield % Comparison
For the Medical Instruments & Supplies subindustry, Bio-Works Technologies AB's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Works Technologies AB FCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio-Works Technologies AB's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Bio-Works Technologies AB's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Works Technologies AB (XSAT:BIOWKS) has a FCF Yield % of -2.69 as of Aug. 21, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Bio-Works Technologies AB and its competitors. According to the industry distribution chart, Bio-Works Technologies AB ranks #500 out of 848 companies in the Medical Devices & Instruments industry, placing it in the top 59%.
Is Bio-Works Technologies AB's FCF Yield % too high?
Bio-Works Technologies AB's current FCF Yield % is -2.69. Based on the distribution chart, Bio-Works Technologies AB ranks #500 out of 848 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Bio-Works Technologies AB has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bio-Works Technologies AB's FCF Yield % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bio-Works Technologies AB ranks #500 out of 848 companies for FCF Yield %. This places Bio-Works Technologies AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Devices & Instruments company?
A good FCF Yield % depends on the Medical Devices & Instruments industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Bio-Works Technologies AB and its competitors. Bio-Works Technologies AB's current FCF Yield % is -2.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Works Technologies AB stock overvalued right now?
Based on GuruFocus' analysis, Bio-Works Technologies AB (XSAT:BIOWKS) is currently considered Fairly Valued. The stock's GF Value™ is kr3.62, compared to a current price of kr3.40 — trading 6.1% below its estimated fair value. The current FCF Yield % is -2.69. Bio-Works Technologies AB's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Bio-Works Technologies AB (XSAT:BIOWKS), the current FCF Yield % is -2.69 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Works Technologies AB (XSAT:BIOWKS) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Works Technologies AB stock appears to be undervalued.
The current stock price of kr3.40 is trading 6.1% below its estimated GF Value™ of kr3.62.
GuruFocus considers Bio-Works Technologies AB to be Fairly Valued.
Key valuation signals for XSAT:BIOWKS:
FCF Yield %: -2.69
GF Value™: kr3.62 vs. price of kr3.40 (6.1% below fair value)
No single metric tells the full story. See the XSAT:BIOWKS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bio-Works Technologies AB is a Sweden-based life science company which is engaged in designing, developing, manufacturing and supplying products for purification and separation of proteins and other molecules. The product line of the company includes activated resin, immobilized metal-ion affinity chromatography resin, ion exchange chromatography resin, size exclusion chromatography resin and others. The company has also developed affinity chromatography technique, BabyBio Columns, OptiBio glass columns for separating proteins, and protein purification. Bio-Works serves various end users such as academic research laboratories, biopharmaceutical companies, the food and beverage industry and others.
68GF Score
Get the complete analysis for XSAT:BIOWKS
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:BIOWKS has been successfully added to your 
